Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cell & Gene Therapy
Pharma
FDA removes barrier to CAR-Ts; move likely to boost uptake
The FDA removed the REMS requirements for currently approved BCMA- and CD19-directed CAR-T therapies and reduced certain post-infusion restrictions.
Angus Liu
Jun 27, 2025 11:14am
FDA investigates 2 deaths after Sarepta Duchenne gene therapy
Jun 25, 2025 10:26am
2nd patient dies after Sarepta's DMD gene therapy Elevidys
Jun 16, 2025 10:58am
Fierce Biotech
At cell and gene roundtable, officials pledge to slash regulations
Jun 5, 2025 2:50pm
Orca hires ex-Legend exec Gavel to target cell therapy market
Jun 5, 2025 11:58am
Novartis, Sarepta tipped to drive genomic therapy sales boom
May 15, 2025 12:18pm
More News
Bluebird investor reluctance pays off with better buyout offer
May 14, 2025 10:40am
Bluebird warns of potential bankruptcy amid buyout delay
May 13, 2025 9:56am
Sarepta sees delays in treatment after Elevidys death report
May 7, 2025 8:03am
As Pfizer bows out, CSL keeps hemophilia gene therapy hopes alive
Apr 11, 2025 10:32am
See more stories
